DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for arterial calcification of infancy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArterial calcification of infancy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arterial calcification of infancy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Generalized arterial calcification of infancy (GACI) is a hereditary disease caused by inactivating variants in ENPP1 (70–75% of cases) or ABCC6 (9–10%). Overall mortality is 55% before six months of age, with 24.4% of cases dying in utero or being stillborn. Mortality is higher with ENPP1 variants (40%) than with ABCC6 variants (10%). In two stillborn infants from 1962, the mineral deposits consisted solely of hydroxyapatite and were regarded as metastatic; both cases had hydramnios, and five of seven known neonatal cases at that time also had hydramnios. An earlier 1954 series of eight cases described calcium deposits on the internal elastic lamina followed by intimal fibrous thickening, with aetiology unknown in infants and lesions in older children considered secondary to renal disease.
Bisphosphonates with anti-calcification properties have been commonly used, but their benefit is controversial: favourable results are reported at one year, and benefit is questionable when treatment is delayed. In Enpp1-deficient mice, recombinant human ENPP1 protein was more effective than bisphosphonates at resolving vascular calcification and the hypertension that leads to cardiac failure in GACI patients. The same enzyme replacement therapy prevented calcification and mortality, improved hypertension and cardiac function, and prevented intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Despite these advances, there is still no ideal therapy for resolution of vascular calcification in GACI.
Rare cases show spontaneous regression with age. Those who survive into adulthood often manifest musculoskeletal complications including osteoarthritis, interosseous membrane ossification, enthesis mineralisation, and cervical spine fusion. What remains missing is clinical trial data in human patients for the enzyme replacement therapy that has shown promise in mice, as well as adequate patient stratification by genotype (ENPP1 versus ABCC6) and timing of treatment initiation. Funding for trials in this ultra-rare disease and consensus on outcome measures beyond survival are also lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Paediatrica · 1962 · 48 citations
Generalized Arterial Calcification Associated with Hydramnios in Two Stillborn Infants
AbstractSummary Histologic, microradiographic and X‐ray crystallographic findings are recorded in two stillborn infants with idiopathic generalized arterial calcification, in one of which there was also nephrocalcinosis. The mineral salt deposits consisted solely of hydroxyapatite and was regarded as metastatic. In both cases there was hydramnios. Since 5 out of 7 known cases of neonatal idiopathic arterial calcification had hydramnios the possibility of a causal connection cannot be ruled out.
Journal of Multidisciplinary Healthcare · 2022 · 34 citations · open access
Generalized Arterial Calcification of Infancy (GACI): Optimizing Care with a Multidisciplinary Approach
AbstractIt is very unusual to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease, which is characterized by severe arterial calcification of medium sized arteries, mostly involving the media with marked intimal proliferation and ectopic mineralization of the extravascular tissues. It is caused by inactivating variants in genes encoding either ENPP1, in a majority of cases (70-75%), or ABCC6, in a minority (9-10%). Despite similar histologic appearances between ENPP1 and ABCC6 deficiencies, including arterial calcification, organ calcification, and cardiovascular calcification, mortality is higher in subjects carrying the ENPP1 versus ABCC6 variants (40% vs 10%, respectively). Overall mortality in individuals with GACI is high (55%) before the age of 6 months, with 24.4% dying in utero or being stillborn. Rare cases show spontaneous regression with age, while others who survive into adulthood often manifest musculoskeletal complications (osteoarthritis and interosseous membrane ossification), enthesis mineralization, and cervical spine fusion. Despite recent advances in the understanding of the genetic mechanisms underlying this disease, there is still no ideal therapy for the resolution of vascular calcification in GACI. Although bisphosphonates with anti-calcification properties have been commonly used for the treatment of CAGI, their benefit is controversial, with favorable results reported at one year and questionable benefit with delayed initiation of treatment. Enzyme replacement therapy with administration of recombinant form of ENPP1 prevents calcification and mortality, improves hypertension and cardiac function, and prevents intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Therefore, newer treatments targeting genes are on the horizon. In this article, we review up to date knowledge of the understanding of GACI, its clinical, pathologic, and etiologic understanding and treatment in support of more comprehensive care of GACI patients.
CALCIFICATION OF THE ARTERIES IN INFANCY AND CHILDHOOD
AbstractEight cases of calcification of the arteries have been described, six infants and two older children. The arterial lesions in all are similar, consisting of a deposit of calcium on the internal elastic lamina followed by more extensive calcification and fibrous thickening of the intima. The aetiology of the infantile condition is unknown. The lesions in the older children are probably secondary to renal disease.
Yearbook of pediatric endocrinology · 2019 · 4 citations
ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy
AbstractIn brief: Generalized arterial calcification of infancy (GACI) is a severe, rare disease characterized by excessive calcification of large and medium sized arteries caused by homozygous loss-of-function mutations in ENPP1. Here, in Enpp1 deficient mice, treatment with recombinant human ENPP1 protein was more effective than bisphosphonates to resolve not only the vascular calcification, but also the hypertension that eventually leads to cardiac failure in GACI patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
